Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bevifimod (PRTX-100), a highly purified variant of Staphylococcal protein A (SpA), is utilized in research on idiopathic thrombocytopenic purpura (ITP) [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Bevifimod (PRTX-100), a highly purified variant of Staphylococcal protein A (SpA), is utilized in research on idiopathic thrombocytopenic purpura (ITP) [1] [2]. |
In vitro | Bevifimod (PRTX-100; concentrations of 250, 25, and 2.5 ng/mL; 48-hour exposure) inhibits the phagocytosis of W632-conditioned platelets by human monocytes in peripheral blood mononuclear cells (PBMC) [1]. |
In vivo | Bevifimod (PRTX-100; 2.5-250 µg/kg; i.v.; biweekly over 4 weeks) normalizes platelet counts within 1-2 weeks without mortality in mice [2]. |
Synonyms | PRTX-100 |
Molecular Weight | N/A |
CAS No. | 2223113-32-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Bevifimod 2223113-32-2 PRTX-100 inhibitor inhibit